3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma
7
Sarcoma, Ewing
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Lymphoma, Large B-Cell, Diffuse
3
Sarcoma, Clear Cell
2
Rhabdomyosarcoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Lymphoma
2
Liposarcoma
2
Hodgkin Disease
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Wilms Tumor
1
Vascular Neoplasms
1
Teratoma
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Pleuropulmonary blastoma
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms, Adipose Tissue
1
Interventions
Rituximab
25
Lenalidomide
21
Cyclophosphamide
20
Prednisone
14
obinutuzumab
12
Vincristine
12
Doxorubicin
11
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
9
Specimen Handling
8
ibrutinib
7
Biopsy
7
fludarabine
6
pembrolizumab
5
fludarabine phosphate
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
zanubrutinib
4
venetoclax
4
tazemetostat
4
Whole-Body Irradiation
4
R-CHOP protocol
4
Prednisolone
3
Mycophenolic Acid
3
Etoposide
3
Cyclosporine
3
tisagenlecleucel
2
polatuzumab vedotin
2
orelabrutinib
2
loncastuximab tesirine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Ifosfamide
×
90 days
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled